Quantitative analysis for Hyperfine, Inc. (HYPR) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (35.0) (grade D). 24 signals analyzed (21 differentiated alt-data).
HYPR stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $1.33 | $1.28 | $1.30 |
| 2026-05-08 | $1.75 | $1.67 | $1.69 |
| 2026-05-20 | $1.49 | $1.42 | $1.48 |
| 2026-06-02 | $1.56 | $1.49 | $1.50 |
| 2026-06-12 | $1.47 | $1.36 | $1.36 |
| 2026-06-25 | $1.70 | $1.45 | $1.69 |
| 2026-07-08 | $1.24 | $1.08 | $1.12 |
| 2026-07-20 | $0.99 | $0.92 | $0.98 |
| 2026-07-30 | $0.99 | $0.90 | $0.93 |
| 2026-08-12 | $0.96 | $0.88 | $0.90 |
| 2026-08-24 | $0.91 | $0.85 | $0.86 |
| 2026-09-03 | $0.84 | $0.80 | $0.84 |
How Hyperfine, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $122M | — |
| PYXS | Pyxis Oncology, Inc. | $127M | 43.0 |
| MIST | Milestone Pharmaceuticals Inc. | $129M | — |
| CNTB | Connect Biopharma Holdings Limited | $131M | — |
View all Health Care stocks by valuation and signals →
Hyperfine, Inc. (HYPR) scores Sell (35.0), and the composite conceals a 74-point disagreement between its dimensions. It is strongest on competitive moat at 92, and weakest on technicals at 18. A stock can carry competitive moat that high while technicals sits at 18; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 92 |
| analyst consensus | 52 |
| technicals | 18 |
StoQuant analyzes 24 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Hyperfine, Inc. (HYPR): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/HYPR"><img src="https://stoquant.com/badge/HYPR.svg" alt="Hyperfine, Inc. (HYPR) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.